Related Experiment Videos
[Mumps in 1998]
1Zakład Epidemiologii, Państwowego Zakładu Higieny, Warszawa.
Abstract:
In 1998 217,452 cases of mumps were reported and attack rate of 562/100,000 was two and a half times higher than in the previous year. More then four percentage (4.7) of cases were admitted to hospitals (10,147) and the percentage of hospitalised children ranged from 0.3% in Chelm voivodeship to 11.2% in Gdańsk voivodeship. Mostly affected were children in the age group 5 to 9 years old in which attack rates ranged from 3,503 to 5,815 per 100,000. Patients in this age group constituted 58% of total number of mumps. MMR vaccine is still not included into the national programme of immunization; instead monovalent measles vaccine is recommended. MMR vaccine is used on voluntary basis.
Insights
In 1998, mumps cases surged significantly, with children aged 5-9 years most affected. This highlights the need for improved vaccination strategies, as the MMR vaccine remains voluntary.
Area of Science:
- Epidemiology
- Public Health
- Immunization
Context:
- In 1998, Poland experienced a substantial increase in mumps cases, with an attack rate of 562/100,000, a 2.5-fold rise from the previous year.
- Mumps significantly impacted children, particularly those aged 5-9 years, who represented 58% of total cases and faced attack rates between 3,503 and 5,815 per 100,000.
- Hospitalization rates varied regionally, from 0.3% to 11.2%, with 4.7% of all mumps cases requiring hospital admission.
Purpose:
- To analyze the epidemiology of mumps in Poland during 1998.
- To identify the most affected age groups and regions.
- To assess the impact of current vaccination policies on mumps incidence.
Summary:
- A significant mumps outbreak occurred in Poland in 1998, with a 2.5-fold increase in attack rates compared to the previous year.
- Children aged 5-9 years were disproportionately affected, constituting 58% of cases.
- Despite the high incidence, the measles, mumps, and rubella (MMR) vaccine is not part of the national immunization program, with only monovalent measles vaccine recommended and MMR used voluntarily.
Impact:
- The findings underscore the epidemiological burden of mumps in a population with suboptimal MMR vaccination coverage.
- The data suggests a critical need to re-evaluate national immunization policies to include the MMR vaccine to control mumps outbreaks.
- This study provides crucial evidence for public health interventions aimed at increasing MMR vaccine uptake and preventing future mumps epidemics.